Meeting
2022 ASCO Annual Meeting
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
Authors
Alice P. Chung
Cedar-Sinai Medical Center, Los Angeles, CA
Alice P. Chung , Marissa K. Srour , Farnaz Dadmanesh , Sungjin Kim , Armando E. Giuliano , Jennifer Wei , Yen Huynh , Josien Haan , Shiyu Wang , Andrea Menicucci , Patricia Dauer , M. William Audeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 585)
DOI
10.1200/JCO.2022.40.16_suppl.585
Abstract #
585
Poster Bd #
356
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study.
First Author: Abirami Sivapiragasam
Poster
2012 Breast Cancer Symposium
Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in U.S. breast cancer (BC) patients.
First Author: Katharine Yao
Poster
2012 Breast Cancer Symposium
Response and long-term outcomes after neoadjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping by MammaPrint and BluePrint.
First Author: Stefan Gluck
Poster
2012 ASCO Annual Meeting
Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U.S. breast cancer (BC) patients.
First Author: Lisette Stork-Sloots